期刊
MOLECULAR ASPECTS OF MEDICINE
卷 81, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.mam.2021.101003
关键词
mRNA vaccines; miRNAs; siRNAs; Aptamers; Riboswitches
资金
- DBT/Wellcome Trust India Alliance Grant [IA/I (S) /17/1/503085]
- DBT Govt. of India
- DST Govt. of India, SERB-SRG grant [SRG/2019/000206]
The versatility of RNAs makes them ideal for overcoming the limitations of small molecule-based drugs in biopharmaceuticals. RNA-based therapeutics face challenges such as instability, delivery to diseased cells, and immunogenicity. Recent advancements in delivery systems and chemical modifications have facilitated the entry of exogenous RNAs into clinical trials for treating infectious diseases.
The functional and structural versatility of Ribonucleic acids (RNAs) makes them ideal candidates for overcoming the limitations imposed by small molecule-based drugs. Hence, RNA-based biopharmaceuticals such as messenger RNA (mRNA) vaccines, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA mimics, anti-miRNA oligonucleotides (AMOs), aptamers, riboswitches, and CRISPR-Cas9 are emerging as vital tools for the treatment and prophylaxis of many infectious diseases. Some of the major challenges to overcome in the area of RNA-based therapeutics have been the instability of single-stranded RNAs, delivery to the diseased cell, and immunogenicity. However, recent advancements in the delivery systems of in vitro transcribed mRNA and chemical modifications for protection against nucleases and reducing the toxicity of RNA have facilitated the entry of several exogenous RNAs into clinical trials. In this review, we provide an overview of RNA-based vaccines and therapeutics, their production, delivery, current advancements, and future translational potential in treating infectious diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据